Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer

Experimental and Molecular Pathology

Volumn 93, Issue 3, 2012, Pages 391-398

  Rivenbark, Ashley G ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Field cancerization

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; EPIGENETICS; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; PARTIAL MASTECTOMY; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PRECANCEROUS CONDITIONS; UBIQUITIN-PROTEIN LIGASES;

EID: 84870684515     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.10.018     Document Type: Review

References (75)

1. Allegra C.J., et al. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ september 22-24, 2009. Journal of the National Cancer Institute 2010, 102:161-169.
2. Allred D.C., et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clinical Cancer Research 2008, 14:370-378.
3. Bae Y.K., et al. Hypermethylation in histologically distinct classes of breast cancer. Clinical Cancer Research 2004, 10:5998-6005.
4. Baylin S. DNA methylation and epigenetic mechanisms of carcinogenesis. Developments in Biologicals 2001, 106:85-87.
5. Baylin S.B., et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 1998, 72:141-196.
6. Berman H., et al. Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis. Cold Spring Harbor Symposia on Quantitative Biology 2005, 70:317-327.
7. Bryan B.B., et al. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Modern Pathology 2006, 19:617-621.
8. Carey L.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA: The Journal of the American Medical Association 2006, 295:2492-2502.
9. Ceol C.J., et al. APC and colon cancer: two hits for one. Nature Medicine 2007, 13:1286-1287.
10. Chai H., Brown R.E. Field effect in cancer-an update. Annals of Clinical and Laboratory Science 2009, 39:331-337.
11. Dabbs D.J., et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Modern Pathology 2006, 19:1506-1511.
12. Dammann R., et al. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Research 2001, 61:3105-3109.
13. Domann F.E., et al. Epigenetic silencing of maspin gene expression in human breast cancers. International Journal of Cancer 2000, 85:805-810.
14. Eden A., et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
15. Fackler M.J., et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. International Journal of Cancer 2003, 107:970-975.
16. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
17. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
18. Feinberg A.P., Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochemical and Biophysical Research Communications 1983, 111:47-54.
19. Feinberg A.P., Vogelstein B. Alterations in DNA methylation in human colon neoplasia. Seminars in Surgical Oncology 1987, 3:149-151.
20. Gaudet F., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
21. Goelz S.E., et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
22. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
23. Hannemann J., et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Research 2006, 8:R61.
24. Harris C.C. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Research 1991, 51:5023 s-5044 s.
25. Heaphy C.M., et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. International Journal of Cancer 2006, 119:108-116.
26. Heaphy C.M., et al. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Research Treat. 2009, 118:229-239.
27. Heppner G.H. Tumor heterogeneity. Cancer Research 1984, 44:2259-2265.
28. Heppner G.H., Miller F.R. The cellular basis of tumor progression. International Review of Cytology 1998, 177:1-56.
29. Heppner G.H., et al. Mammary tumor heterogeneity. Symposium on Fundamental Cancer Research 1983, 36:209-221.
30. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003, 349:2042-2054.
31. Huang T.H., et al. Methylation profiling of CpG islands in human breast cancer cells. Human Molecular Genetics 1999, 8:459-470.
32. Jemal A., et al. Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
33. Jhaveri M.S., Morrow C.S. Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells. Gene 1998, 210:1-7.
34. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nature Genetics 1999, 21:163-167.
35. Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Advances in Experimental Medicine and Biology 2009, 656:85-106.
36. Lewis C.M., et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clinical Cancer Research 2005, 11:166-172.
37. Livasy C.A., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Human Pathology 2007, 38:197-204.
38. Mercer R.R., et al. Molecular discrimination of multiple primary versus metastatic squamous cell cancers of the head/neck and lung. Experimental and Molecular Pathology 2009, 86:1-9.
39. Millikan R.C., et al. Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment 2008, 109:123-139.
40. Momparler R.L. Cancer epigenetics. Oncogene 2003, 22:6479-6483.
41. Narayan A., et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. International Journal of Cancer 1998, 77:833-838.
42. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
43. Nielsen T.O., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 2004, 10:5367-5374.
44. Perou C.M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:9212-9217.
45. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
46. Prat A., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 2010, 12:R68.
47. Rivenbark A.G., et al. DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 2006, 1:32-44.
48. Rivenbark A.G., et al. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Laboratory Investigation 2006, 86:1233-1242.
49. Rivenbark A.G., et al. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Experimental and Molecular Pathology 2007, 83:188-197.
50. Schmitt M.W., et al. Implications of genetic heterogeneity in cancer. Annals of the New York Academy of Sciences 2012, 1267:110-116.
51. Slaughter D.P., et al. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968.
52. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. European Journal of Cancer 2004, 40:2667-2675.
53. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10869-10874.
54. Sorlie T., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8418-8423.
55. Sotiriou C., et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research 2002, 4:R3.
56. Sotiriou C., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10393-10398.
57. Sotiriou C., et al. Genomic and molecular classification of breast cancer. Molecular Oncology of Breast Cancer 2005, 81-95. Jones and Bartlett, Sudbury, M.A. J.S. Ross, G.N. Hortobagyi (Eds.).
58. Tamimi R.M., et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Research 2008, 10:R67.
59. Tsou J.A., et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002, 21:5450-5461.
60. Umbricht C.B., et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001, 20:3348-3353.
61. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine 2002, 347:1999-2009.
62. Van der Auwera I., et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 2010, 10:97.
63. van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
64. Virnig B.A., et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. Journal of the National Cancer Institute 2010, 102:170-178.
65. Vogelstein B., et al. Genetic alterations during colorectal-tumor development. The New England Journal of Medicine 1988, 319:525-532.
66. Wellings S.R., Jensen H.M. On the origin and progression of ductal carcinoma in the human breast. Journal of the National Cancer Institute 1973, 50:1111-1118.
67. Wetzels R.H., et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. American Journal of Pathology 1989, 134:571-579.
68. Widschwendter M., Jones P.A. DNA methylation and breast carcinogenesis. Oncogene 2002, 21:5462-5482.
69. Widschwendter M., et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. Journal of the National Cancer Institute 2000, 92:826-832.
70. Widschwendter M., et al. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2001, 6:193-201.
71. Yan P.S., et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Research 2003, 63:6178-6186.
72. Yan P.S., et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clinical Cancer Research 2006, 12:6626-6636.
73. Yang X., et al. DNA methylation in breast cancer. Endocrine-Related Cancer 2001, 8:115-127.
74. Yates L.R., Campbell P.J. Evolution of the cancer genome. Nature Reviews Genetics 2012, 13:795-806.
75. Zou D., et al. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. The Journal of Pathology 2009, 218:265-272.